Your browser doesn't support javascript.
loading
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
Zhuang, Junling; Shirazi, Fazal; Singh, Ram Kumar; Kuiatse, Isere; Wang, Hua; Lee, Hans C; Berkova, Zuzana; Berger, Allison; Hyer, Marc; Chattopadhyay, Nibedita; Syed, Sakeena; Shi, Judy Qiuju; Yu, Jie; Shinde, Vaishali; Tirrell, Stephen; Jones, Richard Julian; Wang, Zhiqiang; Davis, R Eric; Orlowski, Robert Z.
Afiliação
  • Zhuang J; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
  • Shirazi F; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Singh RK; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Kuiatse I; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Wang H; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Lee HC; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Berkova Z; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Berger A; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Hyer M; Millennium Pharmaceuticals, Inc, a subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; and.
  • Chattopadhyay N; Millennium Pharmaceuticals, Inc, a subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; and.
  • Syed S; Millennium Pharmaceuticals, Inc, a subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; and.
  • Shi JQ; Millennium Pharmaceuticals, Inc, a subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; and.
  • Yu J; Millennium Pharmaceuticals, Inc, a subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; and.
  • Shinde V; Millennium Pharmaceuticals, Inc, a subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; and.
  • Tirrell S; Millennium Pharmaceuticals, Inc, a subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; and.
  • Jones RJ; Millennium Pharmaceuticals, Inc, a subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; and.
  • Wang Z; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Davis RE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Blood ; 133(14): 1572-1584, 2019 04 04.
Article em En | MEDLINE | ID: mdl-30737236
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Enzimas Ativadoras de Ubiquitina / Resposta a Proteínas não Dobradas / Inibidores de Proteassoma / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Enzimas Ativadoras de Ubiquitina / Resposta a Proteínas não Dobradas / Inibidores de Proteassoma / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article